Table 3.
Median CTC number and positive detection rate in the cancer patient blood samples.
| NSCLC (n=3 ) | CRC (n=5 ) | Prostate cancer (n=5 ) | Healthy individual (n=12 ) | |
|---|---|---|---|---|
| panCK (≧3)a | 16 (3/3, 100%)b | 13 (5/5, 100%) | 8 (4/5, 80%) | 0 (0/12, 0%)c |
| p value | <0.001* | 0.002* | <0.001* | |
| CK18 (≧2) | 2 (2/3, 67%) | 3 (3/5, 60%) | 1 (2/5, 40%) | 0 (0/12, 0%) |
| p value | 0.002* | <0.001* | <0.001* | |
| CK7 (≧2) | 4 (3/3, 100%) | 0 (0/5, 0%) | 0 (0/5, 0%) | 0 (2/12, 17%) |
| p value | <0.001* | 0.05 | 0.128 | |
| TTF-1 (≧1) | 2 (3/3, 100%) | 0 (0/5, 0%) | 0 (0/5, 0%) | 0 (0/12, 0%) |
| p value | <0.001* | 0.212 | 0.212 | |
| CK20/CDX2 (≧2) | 0 (0/3, 0%) | 2 (3/5, 60%) | 0 (2/5, 40%) | 0 (2/12, 17%) |
| p value | 0.098 | <0.001* | 0.022* | |
| PSA/PSMA (≧2) | 0 (0/3, 0%) | 0 (0/5, 0%) | 2 (3/5, 60%) | 0 (1/12, 8%) |
| p value | 0.435 | 0.250 | <0.001 |
a
cut-off number established by healthy individual triplicate test.
b
The format was shown as “median CTC number (positive detection rate)”.
c
The positive detection rate in healthy individual group was determined by mean CTC count of triplicate tests.
*
p < 0.05 vs. Healthy individual group.